Clinical Trials Browser

Phase 2 × nilotinib × Gastrointestinal × Clear all

NCT05185947 2025-03-07

Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

Phase 2 Active not recruiting

GastrointestinalGynecologic

Appendiceal Neoplasms, Genital Neoplasms, Female, Necrosis, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms

NCT01863745 2024-08-19

Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

Phase 2 Completed

15 enrolled 7 charts

GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT00633295 2017-06-22

Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor

Phase 2 Completed

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01110668 2017-02-28

Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Phase 2 Completed

GastrointestinalSarcoma

Disease Progression, Gastrointestinal Stromal Tumors

NCT00718562 2017-02-23

Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib

Phase 2 Completed

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00782834 2013-04-22

07060

Phase 2 Terminated

13 enrolled 8 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01270893 2012-08-02

Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)

Phase 2 Withdrawn

GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors